Thamil Annamalai

Nessuna posizione attualmente

Health Technology

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
William Waddill	M	67	PROTAGONIST THERAPEUTICS, INC.	8 anni
Ashok Bhandari	M	-	PROTAGONIST THERAPEUTICS, INC.	7 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
William Rieflin	M	64	XENOPORT, INC.	12 anni
Vincent Angotti	M	56	XENOPORT, INC.	8 anni
Gianna M. Bosko	F	54	XENOPORT, INC.	10 anni
Dennis Fenton	M	72	XENOPORT, INC.	7 anni
Julie Grant	F	41	PROTAGONIST THERAPEUTICS, INC.	2 anni
Gregory T. Bates	M	65	XENOPORT, INC.	-
Catherine Friedman	F	63	XENOPORT, INC.	9 anni
Thomas O'Neil	M	59	PROTAGONIST THERAPEUTICS, INC.	3 anni
David Savello	M	78	XENOPORT, INC.	-
Paul Berns	M	57	XENOPORT, INC.	11 anni
Robert W. Overell	M	69	XENOPORT, INC.	6 anni
Chaitan S. Khosla	M	59	PROTAGONIST THERAPEUTICS, INC.	6 anni
Kenneth J. Nussbacher	M	70	XENOPORT, INC.	10 anni
Jeryl Hilleman	F	67	XENOPORT, INC.	14 anni
Ernest Mario	M	85	XENOPORT, INC.	3 anni
Per G. H. Lofberg	M	76	XENOPORT, INC.	2 anni
Paul Goddard	M	74	XENOPORT, INC.	5 anni
David Edgren	M	-	XENOPORT, INC.	-
Steven Bryant Porter	M	66	IntraBiotics Pharmaceuticals, Inc. IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.	2 anni
May D. Lee	M	-	Essential Therapeutics, Inc. Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections	7 anni
Gary D. Tollefson	M	72	XENOPORT, INC.	4 anni
David J. Wustrow	M	65	XENOPORT, INC.	4 anni
Richard S. Shames	M	-	PROTAGONIST THERAPEUTICS, INC.	4 anni
Bryan Roberts	M	57	XENOPORT, INC.	7 anni
Peter Virsik	M	-	XENOPORT, INC.	10 anni
Williamson Z. Bradford	M	62	IntraBiotics Pharmaceuticals, Inc. IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.	3 anni
Dmitri V. Lissin	M	55	XENOPORT, INC.	4 anni
Lucio Tozzi	M	60	PROTAGONIST THERAPEUTICS, INC.	4 anni
Gary Titus	M	64	IntraBiotics Pharmaceuticals, Inc. IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.	2 anni
William Hodder	M	-	PROTAGONIST THERAPEUTICS, INC.	-
Daniel M. Canafax	M	71	XENOPORT, INC.	5 anni
David Stamler	M	63	XENOPORT, INC.	2 anni
Matt Hogan	M	64	Essential Therapeutics, Inc. Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections	3 anni
Pierre V. Trân	M	64	XENOPORT, INC.	3 anni
Thomas Woiwode	M	52	XENOPORT, INC.	2 anni
Thomas R. Parr	M	70	IntraBiotics Pharmaceuticals, Inc. IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.	1 anni
Annie Li	F	-	IntraBiotics Pharmaceuticals, Inc. IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.	-
Patricia A. Murphy	F	65	PROTAGONIST THERAPEUTICS, INC.	-
Richard A. Farley	M	-	XENOPORT, INC.	-
Robert A. Reed	M	63	XENOPORT, INC.	3 anni
Jerry M. Buysse	M	68	Essential Therapeutics, Inc. Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections	7 anni
Asish Xavier	M	-	PROTAGONIST THERAPEUTICS, INC.	3 anni
Bill Harris	M	65	XENOPORT, INC.	15 anni
Ryan Ward	M	-	XENOPORT, INC.	7 anni

Statistiche

Paese	Relazioni	% del totale
Stati Uniti	46	100.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni